IL276788A - Compounds with activity that causes iron-dependent cell death and methods of using them - Google Patents
Compounds with activity that causes iron-dependent cell death and methods of using themInfo
- Publication number
- IL276788A IL276788A IL276788A IL27678820A IL276788A IL 276788 A IL276788 A IL 276788A IL 276788 A IL276788 A IL 276788A IL 27678820 A IL27678820 A IL 27678820A IL 276788 A IL276788 A IL 276788A
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- methods
- inducing activity
- ferroptosis
- ferroptosis inducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862636614P | 2018-02-28 | 2018-02-28 | |
PCT/US2019/019854 WO2019168999A1 (fr) | 2018-02-28 | 2019-02-27 | Composés ayant une activité inductrice de la ferroptose et procédés de leur utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
IL276788A true IL276788A (en) | 2020-10-29 |
Family
ID=65729467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL276788A IL276788A (en) | 2018-02-28 | 2020-08-18 | Compounds with activity that causes iron-dependent cell death and methods of using them |
Country Status (15)
Country | Link |
---|---|
US (2) | US11098040B2 (fr) |
EP (1) | EP3759075A1 (fr) |
JP (1) | JP7348906B2 (fr) |
KR (1) | KR20200135961A (fr) |
CN (1) | CN112041301A (fr) |
AR (2) | AR114417A1 (fr) |
AU (1) | AU2019229256A1 (fr) |
BR (1) | BR112020017561A2 (fr) |
CA (1) | CA3092143A1 (fr) |
EA (1) | EA202091846A1 (fr) |
IL (1) | IL276788A (fr) |
MX (2) | MX2020008906A (fr) |
SG (1) | SG11202008230PA (fr) |
TW (1) | TW202000663A (fr) |
WO (1) | WO2019168999A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
AU2020228056A1 (en) * | 2019-02-27 | 2021-09-16 | Ferro Therapeutics, Inc. | Compounds with ferroptosis inducing activity and methods of their use |
CN110511253B (zh) * | 2019-09-04 | 2023-10-13 | 上海药明康德新药开发有限公司 | DNA编码化合物库构建中On-DNA四氢-β-咔啉类化合物的合成方法 |
CN110627786B (zh) * | 2019-10-29 | 2020-11-24 | 株洲千金药业股份有限公司 | 一种他达拉非中间体的制备方法 |
EP4076434A1 (fr) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer |
US11998534B2 (en) * | 2020-02-12 | 2024-06-04 | Eubulus Biotherapeutics Inc. | GPX4 inhibitor in combination with anticancer agent for treating proliferative disease |
CN115243719A (zh) * | 2020-03-06 | 2022-10-25 | 北京先通生物医药技术有限公司 | CTB006与Ponatinib联合应用 |
TW202227399A (zh) * | 2020-08-26 | 2022-07-16 | 美商費洛醫療公司 | 化合物及使用方法 |
WO2022216066A1 (fr) * | 2021-04-08 | 2022-10-13 | 서울대학교산학협력단 | Biomarqueur pour l'estimation du pronostic chez des patients atteints de cancer et son utilisation |
CN113336748B (zh) * | 2021-04-12 | 2022-03-25 | 北京大学 | 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物 |
US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
WO2024015637A1 (fr) * | 2022-07-15 | 2024-01-18 | Ferro Therapeutics, Inc. | Inhibiteurs de la glutathion peroxydase 4 (gpx4) pour le traitement du cancer |
WO2024039860A1 (fr) * | 2022-08-19 | 2024-02-22 | Olema Pharmaceuticals, Inc. | Dérivés de 2,3,4,9-tétrahydro-1h-pyrido[3,4-b]indole en tant que modulateurs du récepteur des oestrogènes pour le traitement du cancer |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9514465D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
WO2001094345A2 (fr) | 2000-06-07 | 2001-12-13 | Lilly Icos Llc | Composes chimiques |
US20030153575A1 (en) * | 2000-06-08 | 2003-08-14 | Orme Mark W. | Tetracyclic diketopiperazine compounds as pdev inhibitors |
ATE297926T1 (de) * | 2000-10-02 | 2005-07-15 | Lilly Icos Llc | Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen |
US6960587B2 (en) | 2000-11-08 | 2005-11-01 | Lilly Icos Llc | Condensed pyrazindione derivatives as PDE inhibitors |
EP2324886A1 (fr) * | 2005-07-29 | 2011-05-25 | Concert Pharmaceuticals Inc. | Nouveaux analogues deutériés de tadalafil |
EP1914235A1 (fr) * | 2006-10-10 | 2008-04-23 | Universite de Lille 2 Droit et Santé | Dérivés chirales tetra-hydro beta-carbolines en tant qu'agents antiparasitaires |
WO2008103470A2 (fr) | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Composés létaux dépendants du signal de ras oncogénique |
FR2916200A1 (fr) * | 2007-05-18 | 2008-11-21 | Fourtillan Snc | Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique |
US9169247B2 (en) * | 2009-11-20 | 2015-10-27 | Southern Research Institute | Tetrahydro-beta-carboline derivatives, synthesis and use thereof |
US9695133B2 (en) * | 2012-07-13 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use |
WO2015051149A1 (fr) | 2013-10-04 | 2015-04-09 | The Trustees Of Columbia University In The City Of New York | Analogues de sorafenib et leurs utilisations |
EP3094332B1 (fr) | 2014-01-15 | 2018-09-12 | The Trustees of Columbia University in the City of New York | Analogues carbonylés de l'érastine et leur utilisation |
EP3233070A4 (fr) | 2014-12-16 | 2018-08-08 | ADT Pharmaceuticals, LLC | Composés d'acétamide indényle inhibiteur de ras, compositions et utilisations |
CN108377643B (zh) | 2015-05-29 | 2021-09-21 | 纪念斯隆凯特琳癌症中心 | 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法 |
KR102099159B1 (ko) | 2015-11-12 | 2020-04-10 | 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 | 아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법 |
WO2017120445A1 (fr) | 2016-01-07 | 2017-07-13 | The Broad Institute, Inc. | Composés et des méthodes pour augmenter l'infiltration tumorale par des cellules immunitaires |
AR107314A1 (es) | 2016-01-08 | 2018-04-18 | Ecolab Usa Inc | Modificadores de la reología del petróleo pesado para la mejora del flujo durante las operaciones de producción y transporte |
EP3411034B1 (fr) | 2016-02-05 | 2020-11-25 | Inventisbio Inc. | Agents de dégradation sélectifs des récepteurs des strogènes et leurs utilisations |
WO2018118711A1 (fr) | 2016-12-19 | 2018-06-28 | The Trustees Of Columbia University In The City Of New York | Inducteurs de ferroptose à petites molécules |
WO2018218087A1 (fr) | 2017-05-24 | 2018-11-29 | K-Gen, Inc. | Méthodes de traitement du cancer |
EP4085919A3 (fr) | 2017-07-21 | 2023-02-08 | Novartis AG | Compositions et procédés permettant de traiter un cancer |
WO2019106434A1 (fr) | 2017-12-01 | 2019-06-06 | Collaborative Medicinal Development Pty. Ltd. | Dérivés aromatiques hétérocycliques pour le traitement de troubles liés à la ferroptose |
US20200383943A1 (en) | 2017-12-04 | 2020-12-10 | Memorial Sloan Kettering Cancer Center | Methods of cancer treatment via regulated ferroptosis |
CN109796424A (zh) | 2019-02-19 | 2019-05-24 | 四川大学 | 一种抑制铁死亡的小分子化合物及其制备方法与应用 |
AU2020228056A1 (en) | 2019-02-27 | 2021-09-16 | Ferro Therapeutics, Inc. | Compounds with ferroptosis inducing activity and methods of their use |
-
2019
- 2019-02-27 BR BR112020017561-7A patent/BR112020017561A2/pt unknown
- 2019-02-27 CN CN201980028824.0A patent/CN112041301A/zh active Pending
- 2019-02-27 JP JP2020545666A patent/JP7348906B2/ja active Active
- 2019-02-27 KR KR1020207027582A patent/KR20200135961A/ko unknown
- 2019-02-27 EP EP19710558.8A patent/EP3759075A1/fr active Pending
- 2019-02-27 WO PCT/US2019/019854 patent/WO2019168999A1/fr unknown
- 2019-02-27 TW TW108106912A patent/TW202000663A/zh unknown
- 2019-02-27 MX MX2020008906A patent/MX2020008906A/es unknown
- 2019-02-27 AU AU2019229256A patent/AU2019229256A1/en active Pending
- 2019-02-27 US US16/287,805 patent/US11098040B2/en active Active
- 2019-02-27 EA EA202091846A patent/EA202091846A1/ru unknown
- 2019-02-27 CA CA3092143A patent/CA3092143A1/fr active Pending
- 2019-02-27 SG SG11202008230PA patent/SG11202008230PA/en unknown
- 2019-02-28 AR ARP190100499A patent/AR114417A1/es unknown
-
2020
- 2020-02-27 AR ARP200100540A patent/AR118205A1/es unknown
- 2020-08-18 IL IL276788A patent/IL276788A/en unknown
- 2020-08-26 MX MX2023001527A patent/MX2023001527A/es unknown
-
2021
- 2021-07-06 US US17/368,708 patent/US20230039846A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20190263802A1 (en) | 2019-08-29 |
AR118205A1 (es) | 2021-09-22 |
MX2020008906A (es) | 2021-02-26 |
SG11202008230PA (en) | 2020-09-29 |
AR114417A1 (es) | 2020-09-02 |
EA202091846A1 (ru) | 2021-06-01 |
US20230039846A1 (en) | 2023-02-09 |
JP2021515010A (ja) | 2021-06-17 |
BR112020017561A2 (pt) | 2020-12-22 |
JP7348906B2 (ja) | 2023-09-21 |
KR20200135961A (ko) | 2020-12-04 |
TW202000663A (zh) | 2020-01-01 |
AU2019229256A1 (en) | 2020-09-17 |
EP3759075A1 (fr) | 2021-01-06 |
US11098040B2 (en) | 2021-08-24 |
CN112041301A (zh) | 2020-12-04 |
MX2023001527A (es) | 2023-03-06 |
WO2019168999A1 (fr) | 2019-09-06 |
CA3092143A1 (fr) | 2019-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276788A (en) | Compounds with activity that causes iron-dependent cell death and methods of using them | |
IL290809A (en) | Tau-protein targeted protacs and related methods of use | |
IL292094A (en) | Neoantigens and methods for using them | |
IL285730A (en) | Compounds with proptosis-inducing activity and methods of using them | |
IL273918A (en) | Trispecific proteins and methods of use | |
ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
IL292810A (en) | Therapeutic compounds and methods of use | |
IL277963A (en) | Bicyclic carboxamides and methods of using them | |
IL276687A (en) | Trialkyne coupling agents and methods of using them | |
IL265955A (en) | Therapeutic compounds and methods of use thereof | |
HK1252567A1 (zh) | 被取代的苯甲酰胺和其使用方法 | |
ZA202005674B (en) | Glucoamylases and methods of use thereof | |
IL289748A (en) | Heterodimers and methods of using them | |
IL283782A (en) | Analosomes and methods of use | |
IL287966A (en) | Automatic injector and associated methods of use | |
GB201715194D0 (en) | Compounds and their therapeutic use | |
IL291180A (en) | Bee vaccines and methods of use | |
HK1258056A1 (zh) | 治療性化合物和其使用方法 | |
IL276792A (en) | Inhaler and methods for using it | |
ZA201908276B (en) | Charge-tagged nucleotides and methods of use thereof | |
GB2589398B (en) | Compounds and methods of use | |
GB201900741D0 (en) | Liver-specifc inducible prometers and methods of use thereof | |
GB201709186D0 (en) | Construction block and methods of use |